Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

bruno farmaceutici s.p.a. - metformina e sitagliptina - metformina e sitagliptina

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - sitagliptinum - sitagliptin spirig hc 25 mg. filmtabletten - sitagliptini hydrochloridum monohydricum corresp. sitagliptinum 25 mg, calcii hydrogenophosphas, cellulosum microcristallinum, carmellosum natricum conexum, natrii stearylis fumaras, magnesii stearas, Überzug: lactosum monohydricum 1.2 mg, hypromellosum, e 171, triacetinum, e 172 (rubrum), pro compresso obducto corresp. natrium 0.6 mg. - antidiabetico - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - sitagliptinum - sitagliptin spirig hc 50 mg. filmtabletten - sitagliptini hydrochloridum monohydricum corresp. sitagliptinum 50 mg, calcii hydrogenophosphas, cellulosum microcristallinum, carmellosum natricum conexum, natrii stearylis fumaras, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogola, talcum, e 172 (flavum), e 172 (rubrum), pro compresso obducto corresp. natrium 1.2 mg. - antidiabetico - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - sitagliptinum - sitagliptin spirig hc 100 mg. filmtabletten - sitagliptini hydrochloridum monohydricum corresp. sitagliptinum 100 mg, calcii hydrogenophosphas, cellulosum microcristallinum, carmellosum natricum conexum, natrii stearylis fumaras, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogola, talcum, e 172 (flavum), e 172 (rubrum), pro compresso obducto corresp. natrium 2.39 mg. - antidiabetico - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabete mellito, tipo 2 - farmaci usati nel diabete - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - sitagliptinum - compresse rivestite con film - sitagliptinum 25 mg ut sitagliptini hydrochloridum monohydricum, calcii hydrogenophosphas, cellulosum microcristallinum, carmellosum natricum conexum, magnesii stearas, natrii stearylis fumaras, Überzug: hypromellosum, hydroxypropylcellulosum, macrogolum 6000, e 171, e 172 (flavum), e 172 (rubrum), talcum, pro compresso obducto corresp. natrium max. 0.441 mg. - il diabete mellito di tipo 2 - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - sitagliptinum - compresse rivestite con film - sitagliptinum 50 mg ut sitagliptini hydrochloridum monohydricum, calcii hydrogenophosphas, cellulosum microcristallinum, carmellosum natricum conexum, magnesii stearas, natrii stearylis fumaras, Überzug: hypromellosum, hydroxypropylcellulosum, macrogolum 6000, e 171, e 172 (flavum), e 172 (rubrum), talcum, pro compresso obducto corresp. natrium max. 0.891 mg. - il diabete mellito di tipo 2 - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - sitagliptinum - compresse rivestite con film - sitagliptinum 100 mg ut sitagliptini hydrochloridum monohydricum, calcii hydrogenophosphas, cellulosum microcristallinum, carmellosum natricum conexum, magnesii stearas, natrii stearylis fumaras, Überzug: hypromellosum, hydroxypropylcellulosum, macrogolum 6000, e 171, e 172 (flavum), e 172 (rubrum), e 172 (nigrum), talcum, pro compresso obducto corresp. natrium max. 1.792 mg. - il diabete mellito di tipo 2 - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

axapharm ag - sitagliptinum - compresse rivestite con film - sitagliptinum 25 mg ut sitagliptini hydrochloridum monohydricum, cellulosum microcristallinum, calcii hydrogenophosphas, carmellosum natricum conexum, natrii stearylis fumaras, magnesii stearas, Überzug: poly(vinylis acetas), e 171, macrogola, talcum, e 172 (flavum), e 172 (rubrum), pro compresso obducto corresp. natrium 0.28 mg. - farmaco antidiabetico orale - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

axapharm ag - sitagliptinum - compresse rivestite con film - sitagliptinum 50 mg ut sitagliptini hydrochloridum monohydricum, cellulosum microcristallinum, calcii hydrogenophosphas, carmellosum natricum conexum, natrii stearylis fumaras, magnesii stearas, Überzug: poly(vinylis acetas), e 171, macrogola, talcum, e 172 (flavum), e 172 (rubrum), pro compresso obducto corresp. natrium 0.56 mg. - farmaco antidiabetico orale - synthetika